Literature DB >> 18926476

Metoclopramide and extrapyramidal symptoms: a case report.

Daniel D Moos1, Debra J Hansen.   

Abstract

Metoclopramide is a useful medication in the anesthesia provider's armamentarium. Its primary indication in the preoperative phase is to reduce gastric contents and increase lower esophageal sphincter tone for pharmacologic pulmonary aspiration prophylaxis. Metoclopramide can precipitate extrapyramidal symptoms (EPS)/drug-induced movement disorders (DIMD). Tardive dyskinesia and Parkinsonism is generally seen after long-term use, whereas dystonia and akathisia can occur after a single dose of metoclopramide. Recognition of dystonia and/or akathisia by the perianesthesia nurse after the administration of metoclopramide is important for prompt treatment of this distressing condition. It is imperative that the perianesthesia nurse is knowledgeable in metoclopramide's basic pharmacology, uses as an anesthetic adjunct, guidelines for administration, and EPS/DIMD associated reactions, as well as measures that may reduce the incidence and/or facilitate treatment of this medication-induced condition. This case report presents a male patient in his 40s experiencing akathisia after a single 10-mg dose of metoclopramide.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18926476     DOI: 10.1016/j.jopan.2008.07.006

Source DB:  PubMed          Journal:  J Perianesth Nurs        ISSN: 1089-9472            Impact factor:   1.084


  8 in total

1.  Anaesthetic management of a patient with a unique combination of anti-N-methyl-D-aspartate receptor encephalitis and stiff-person syndrome.

Authors:  Mohammad Hadi Gharedaghi; Arjang Khorasani; Nebojsa Nick Knezevic; Farzad Ebrahimi
Journal:  BMJ Case Rep       Date:  2018-05-07

2.  Investigation of the effect of metoclopramide on proliferation signal molecules in breast tissue.

Authors:  Nurcan Umur; Selda İldan Çalım; Gülce Naz Yazıcı; Seren Gulsen Gurgen
Journal:  Int J Exp Pathol       Date:  2022-03-03       Impact factor: 2.793

3.  Extrapyramidal side effects after metoclopramide administration in a post-anesthesia care unit -A case report-.

Authors:  Youn Yi Jo; Yong Beom Kim; Mi Ran Yang; Young Jin Chang
Journal:  Korean J Anesthesiol       Date:  2012-09-14

4.  Off-label prescribing patterns of antiemetics in children: a multicenter study in Italy.

Authors:  Davide Zanon; Luca Gallelli; Francesca Rovere; Rossella Paparazzo; Natalia Maximova; Marzia Lazzerini; Antonio Reale; Tiziana Corsetti; Salvatore Renna; Tullia Emanueli; Francesco Mannelli; Francesco Manteghetti; Liviana Da Dalt; Caterina Palleria; Nicola Banchieri; Antonio Urbino; Mario Miglietta; Giovanni Cardoni; Adriana Pompilio; Alberto Arrighini; Clara Lazzari; Gianni Messi
Journal:  Eur J Pediatr       Date:  2012-12-04       Impact factor: 3.183

5.  A Pharmacogenetic Discovery: Cystamine Protects Against Haloperidol-Induced Toxicity and Ischemic Brain Injury.

Authors:  Haili Zhang; Ming Zheng; Manhong Wu; Dan Xu; Toshihiko Nishimura; Yuki Nishimura; Rona Giffard; Xiaoxing Xiong; Li Jun Xu; J David Clark; Peyman Sahbaie; David L Dill; Gary Peltz
Journal:  Genetics       Date:  2016-03-18       Impact factor: 4.562

6.  Evaluation of the pharmacokinetics of trazpiroben (TAK-906) in the presence and absence of the proton pump inhibitor esomeprazole.

Authors:  Jatinder Kaur Mukker; George Dukes; Lisi Wang; Susanna Huh; Polyna Khudyakov; Mitsuhiro Nishihara; Chunlin Chen
Journal:  Clin Transl Sci       Date:  2022-02-26       Impact factor: 4.438

7.  Ondansetron versus metoclopramide for managing hyperemesis gravidarum: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Ebraheem Albazee; Lina Almahmoud; Firas Al-Rshoud; Dima Sallam; Wardah Albzea; Rawan Alenezi; Saeed Baradwan; Ahmed Abu-Zaid
Journal:  Turk J Obstet Gynecol       Date:  2022-06-27

8.  Adding metoclopramide to paroxetine induced extrapyramidal symptoms and hyperprolactinemia in a depressed woman: a case report.

Authors:  Ryohei Igata; Hikaru Hori; Kiyokazu Atake; Asuka Katsuki; Jun Nakamura
Journal:  Neuropsychiatr Dis Treat       Date:  2016-09-01       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.